Another regulatory approach to mandate vaccines could have withstood judicial scrutiny.
Although much more work remains, the current Administration has made historic progress in advancing equity.
The Biden Administration should exert international and domestic pressure to waive COVID-19 vaccine patents.
Antitrust experts from the University of Pennsylvania reflect on the possible consequences of the recent Biden executive order on competition.
Scholar argues that U.S. financial regulatory agencies must reflect the people they serve.
President Biden’s first executive actions provide lessons on presidential authority and ambition.
President Trump’s last executive actions and President Biden’s early ones reveal fleeting nature of executive power.
The economic principles underlying cost-benefit analysis exclude future impacts.
The Biden Administration should reject arguments to re-incarcerate people released from prison during the COVID-19 pandemic.
The Biden memorandum signals continuity in some areas of regulatory practice and dramatic shifts in others.
President Biden’s memo could transform the mission of regulatory review by expanding OIRA’s role.
The Biden memo on improving regulatory review reintroduces competent, bipartisan cost-benefit analysis.